CRT 2025
Technology and Innovation
Renal Denervation and Hypertension Therapies
Michael J. Bloch, MD
Medical Director, Vascular Care
Renown Institute for Heart and Vascular Health
reno, Nevada, United States
Disclosure(s): Amgen: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); baralogics: Consulting Fees (e.g., advisory boards) (Ongoing); corcept: Consulting Fees (e.g., advisory boards) (Ongoing); esperion: Consulting Fees (e.g., advisory boards) (Ongoing); idorsia pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); janssen: Consulting Fees (e.g., advisory boards) (Ongoing); medtronic.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); Recor Medical, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); SoniVie: Grant/Research Support (Ongoing)